Needham & Company downgraded Seattle Genetics (NASDAQ: SGEN) from Buy to Hold on valuation following Q4 results.

"Seattle Genetics ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE